TSVT Overview

Investigation of Companies: Halper Sadeh LLC is investigating Berkshire Hills Bancorp's merger with Brookline Bancorp, 2seventy bio's sale to Bristol Myers Squibb, and Redfin's sale to Rocket Companies for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.

Legal Support for Shareholders: The firm offers free consultations to affected shareholders regarding their rights and options, emphasizing that they operate on a contingent fee basis, meaning no upfront legal fees are required.

Opdivo Approval: Bristol Myers Squibb's Opdivo (nivolumab) has received a positive recommendation from the European Medicines Agency for use in combination with chemotherapy as neoadjuvant treatment for high-risk non-small cell lung cancer, based on favorable results from the CheckMate-77T trial.

Expansion of Product Portfolio: The company also announced the approval of a subcutaneous formulation of Opdivo and the launch of Cobenfy, an oral medication for schizophrenia, which is expected to enhance its revenue base amid competition from generics.

Earnings Release: $TSVT is set to announce its quarterly earnings on March 25th, with analysts predicting revenue of approximately $11.83 million and a loss of $0.27 per share.

Insider Trading Activity: In the past six months, $TSVT insiders have conducted 20 stock sales without any purchases, while institutional investors show mixed activity with 48 adding shares and 51 reducing their positions.

Investigation of Companies: Halper Sadeh LLC is investigating Radius Recycling, Endo, 2seventy bio, and Redfin for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their recent transactions.

Legal Support for Shareholders: The firm offers free consultations to affected shareholders regarding their rights and options, potentially seeking increased compensation or additional disclosures on behalf of investors.

Investigation of Proposed Sale: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of 2seventy bio, Inc. to Bristol Myers Squibb, where shareholders would receive $5.00 per share.

Legal Rights and Valuation Concerns: KSF is assessing whether the sale price adequately reflects the company's value and invites shareholders to discuss their legal rights regarding the transaction.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.